Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
株式のランク #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
株価
$64.97
最終同期: 2024-05-20
時価総額
$1.97B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Alpine Immune Sciences, Inc. (ALPN)

カテゴリー

Alpine Immune Sciences, Inc.(ALPN)のP/B比率
August 2026 時点のP/B比率 TTM: 9.91
Alpine Immune Sciences, Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 9.91 です。2022 年末時点でのP/B比率は 1.37 でした。
Alpine Immune Sciences, Inc. の P/B 比率の履歴(2012 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) 9.91 240.41%
2023 2.91 112.16%
2022 1.37 -53.07%
2021 2.92 -30.87%
2020 4.22 76.50%
2019 2.39 109.27%
2018 1.14 24.25%
2017 0.92 46.95%
2016 0.63 -27.94%
2015 0.87 -110.05%
2014 -8.64 479.51%
2013 -1.49 0.00%
2012 0.00 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.3419 -35.98%
US
6.2413 -36.99%
NL
2.5054 -74.71%
AU
3.7087 -62.56%
US
- -
CH